awmsg logo



vismodegib (Erivedge®)


Reference No. 1037

Publication date:
12/09/2017


Appraisal information

vismodegib (Erivedge®) 150 mg capsule


Company: Roche Products Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 11/01/2017
AWMSG meeting date: 26/04/2017
   
   
Submission Type: Directed
Status: Superseded
Advice No: 0917
Ministerial ratification: 11/09/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA489) NICE GUIDANCE ISSUED NOVEMBER 2017 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download